NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH).
瑞士臨床階段生物製藥公司NLS Pharmaceutics Ltd.（納斯達克股票代碼：NLSP）（納斯達克股票代碼：NLSP）（“NLS” 或 “公司”）是一家致力於罕見和複雜中樞神經系統疾病開創性療法的瑞士臨床階段生物製藥公司，今天宣佈了其在邁阿密的美國臨床心理藥理學會（ASCP）進行的臨床前研究 KO-874 的令人鼓舞的結果。該研究評估了馬辛多爾對下丘腦外側（LH）OREXIN-b-Saporin（OX-B-SAP）病變誘發的發作性睡眠樣症狀的大鼠模型夜間活動的神經保護作用。
譯文內容由第三人軟體翻譯。